Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Nitrite Infusion in Islet Cell Transplantation

7. oktober 2020 opdateret af: Blair Smith, University of Alabama at Birmingham

Nitrite Infusion in Islet Cell Transplantation: Test of Clinical Efficacy and Determination of Cytoprotective Mechanisms

This study seeks to investigate the effects of administering nitrite to pancreatic islet cells that have been removed from a patient for autotransplantation.

Studieoversigt

Detaljeret beskrivelse

Patients diagnosed with chronic pancreatitis or recurrent acute pancreatitis may acquire insulin-dependent diabetes due to islet cell destruction. Therefore, islet cell autotransplantation is the optimal therapeutic approach for many of these patients. Islet cell autotransplantation is typically done by excision of the pancreas, followed by isolation of the islet cells and then infusion of these cells into the sinusoids of the liver. Isolation of the islet cells occurs in an ischemic and hypoxic environment, resulting in ischemia reperfusion (IR) injury and destruction of islet cells following infusion into the sinusoids. Hence, strategies to prevent IR injury and subsequent islet cell destruction, such as the administration of inhaled nitric oxide (NO) or sodium nitrite (NaNO2) could enhance islet cell survival following reperfusion, also decreasing long-term insulin requirement. The purpose of this study is to determine if NO administered by infusion in patients undergoing islet cell auto transplantation, will inhibit islet cell destruction, increase diabetes cure rate (decrease the amount of and/or the need for long-term insulin requirement), decrease the ischemic injury (reduces the injury to the islet cells from a decrease in oxygen levels during procurement of the islet cells) during islet cell procurement, and decrease IR injury following islet cell infusion. The primary endpoints of the study are exogenous insulin use, HgbA1c levels post-operatively, and blood glucose levels.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

4

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • University of Alabama at Birmingham

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients greater than or equal to 18 years of age
  • Scheduled to undergo Islet Cell auto-transplantation by Dr. Jared White or Dr. Bart Rose
  • Subjects who can provide informed written consent and are willing to do so

Exclusion Criteria:

-Any patient with liver disease or unsuitable for surgery (as determined by the surgeon)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Kontrolgruppe
A saline infusion will be administered during the pre-isolation and post-isolation phases.
Eksperimentel: Pre-Isolation Infusion
A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
Eksperimentel: Post-Isolation Infusion
A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Prior to Infusion Blood Glucose Serum Levels
Tidsramme: Between the time of induction and the time immediately prior to infusion of either nitrite or saline
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
Between the time of induction and the time immediately prior to infusion of either nitrite or saline
Pre-islet Cell Infusion Blood Serum Glucose Levels
Tidsramme: Five minutes prior to the infusion of islet cells
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
Five minutes prior to the infusion of islet cells
20 Minutes After Islet Cells Blood Serum Glucose Levels
Tidsramme: 20 minutes after the infusion of Islet Cells
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
20 minutes after the infusion of Islet Cells
40 Minutes After Islet Cells Blood Serum Glucose Levels
Tidsramme: 40 minutes after the infusion of Islet Cells
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
40 minutes after the infusion of Islet Cells
24 Hours Post Operative Blood Samples Serum Glucose Levels
Tidsramme: 24 hours post operatively
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
24 hours post operatively
48 Hours Post Operative Blood Samples Serum Glucose Levels
Tidsramme: 48 hours post operatively
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
48 hours post operatively
72 Hours Post Operative Blood Samples Serum Glucose Levels
Tidsramme: 72 hours post operatively
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
72 hours post operatively
96 Hours Post Operative Blood Samples Serum Glucose Levels
Tidsramme: 96 hours post operatively
Blood serum glucose levels will be measured from a blood sample of the amount of 3-5 cc.
96 hours post operatively

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Blair Smith, MD, University of Alabama at Birmingham

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. maj 2017

Primær færdiggørelse (Faktiske)

27. juni 2019

Studieafslutning (Faktiske)

27. juni 2019

Datoer for studieregistrering

Først indsendt

21. maj 2018

Først indsendt, der opfyldte QC-kriterier

21. maj 2018

Først opslået (Faktiske)

1. juni 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. oktober 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. oktober 2020

Sidst verificeret

1. oktober 2020

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Control

3
Abonner